|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
1995-9-7
|
|
pubmed:abstractText |
Based on experimental data, HMG CoA reductase inhibitors are theoretically contraindicated in patients with porphyria. These new cholesterol lowering drugs are increasingly being prescribed. We report the first case of drug-related porphyria cutanea tarda due to HMG CoA reductase inhibitors.
|
|
pubmed:language |
fre
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0151-9638
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
121
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
817-9
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
[Porphyria cutanea tarda induced by HMG CoA reductase inhibitors: simvastatin, pravastatin].
|
|
pubmed:affiliation |
Service de Dermatologie, Hôpital Nord, CHU Saint-Etienne.
|
|
pubmed:publicationType |
Journal Article,
English Abstract,
Case Reports
|
